Double-digit gains for its Digestive Health category helped Bayer Consumer Health record a 5.3% rise in adjusted second-quarter sales to €1.46bn ($1.59bn).
Introducing German brand Iberogast to the US was key to the 14.5% adjusted sales growth recorded by Digestive Health in Q2, with Bayer Consumer’s CFO Magnus Schellnock describing the roll...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?